Who are metformin/glimepiride combination's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-glimepiride-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

metformin/glimepiride combination — Competitive Intelligence Brief

metformin/glimepiride combination (metformin/glimepiride combination) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide/Sulfonylurea combination. Area: Endocrinology/Diabetes.

marketed Biguanide/Sulfonylurea combination AMP-activated protein kinase (AMPK) pathway; ATP-sensitive potassium channels (KATP) Endocrinology/Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

metformin/glimepiride combination (metformin/glimepiride combination) — Laboratorios Silanes S.A. de C.V.. Metformin reduces hepatic glucose production and improves insulin sensitivity, while glimepiride stimulates pancreatic beta cells to increase insulin secretion, together lowering blood glucose in type 2 diabetes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
metformin/glimepiride combination TARGET	metformin/glimepiride combination	Laboratorios Silanes S.A. de C.V.	marketed	Biguanide/Sulfonylurea combination	AMP-activated protein kinase (AMPK) pathway; ATP-sensitive potassium channels (KATP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide/Sulfonylurea combination class)

Laboratorios Silanes S.A. de C.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metformin/glimepiride combination — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-glimepiride-combination. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab